HomeSGX-LISTED COMPANIESGuocoLand Limited: FY2025 Financial Results and Outlook

GuocoLand Limited: FY2025 Financial Results and Outlook

Published on

spot_img

GuocoLand Limited FY2025 reflects a robust Singapore property market, fueled by strong demand and successful integrated developments. The “twin-engine growth strategy” continues creating value, supported by prudent capital management and a dedication to sustainable, high-quality projects. Strategic land acquisitions are set for future expansion.

• Witness flagship integrated developments achieving strong commitment across residential and commercial sectors

• Explore strategic land acquisitions poised to expand a quality portfolio and transform neighbourhoods

• Uncover the vision behind transforming neighbourhoods with user-centric, green designs and a diversified tenant base

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...